NOTICE OF EXTRAORDINARY GENERAL MEETING IN DIAMYD MEDICAL AKTIEBOLAG

Diamyd Medical (Reg. No. 556242-3797) has convened an extraordinary general meeting on 8 April 2026 at 13:00 CEST at Advokatfirman Vinge, Smålandsgatan 20, Stockholm; registration opens at 12:30 CEST. The notice calls shareholders to participate in the EGM; participation details are provided in the full notice (article truncated). This is a routine corporate governance announcement for the Stockholm-listed biotech and is unlikely to have material market impact.

Analysis

An imminent EGM in a small-cap biotech is an event-driven lever: the most common outcomes are capital raises, board/management changes, or strategic partnerships. Each has asymmetric market impact — a rights issue or convertible issue typically compresses equity value by 15–40% within days, while a licensing deal or credible strategic investor can rerate shares by 30–100% over months due to de‑risking of clinical/regulatory cash flow timelines.

Second-order winners/losers depend on the route chosen: a financing favors local investment banks, short-term CRO revenues and CDMOs that win follow-on manufacturing mandates, while a licensing sale benefits larger diabetes/immune players that can quickly scale and commercialize (picking up optionality at low marginal cost). A board shakeup that signals an M&A process will make arbitrageurs and dedicated biotech acquirers the marginal buyers — generalist small-cap funds are likely to sell into that flow.

Timing and risks: the immediate window is days around the EGM for vote outcomes, with substantive implementation (capital flow, partnership contracts) taking 2–12 weeks and de‑risking of clinical readouts or commercial milestones taking 6–24 months. Tail risks include last‑minute consent solicitations that reverse a market move, activist demands that delay execution, or failed vote outcomes that trigger management exits and deeper drawdowns.

The cleanest edge is event-driven sizing and volatility capture rather than directional fundamental conviction. Position sizing should reflect binary outcomes and liquidity constraints: expect >20% intraday moves on headline decisions, but also limited ability to scale in/out without moving the book in thinly traded names.

Key Decisions for Investors

• Short Diamyd Medical (DIAMYD.ST) into the EGM — position 2–4% notional, horizon 1–3 months. Rationale: hedge against a high-probability financing/dilution scenario; target 30% downside if a rights issue/convertible is announced; hard stop at 15% adverse move to limit gamma risk.
• Buy downside options if available: purchase 3‑month DIAMYD.ST puts ~15% OTM (or buy an at-the-money put if 2-way liquidity is poor). Pay up to 2–3% of notional premium; target 3–5x payoff if dilution or management departure is confirmed within the window.
• Pairs trade: long Novo Nordisk (NOVO‑B.CO) 6–12 month view (2% portfolio) and short DIAMYD.ST (equal notional). This captures asymmetric payoff if Diamyd pursues licensing with a larger diabetes player; expected risk/reward ~+15–25% vs limited single-digit downside from the Novo leg, netting a favorable skew.
• Volatility capture: if options liquidity supports it, buy a 2–4 week straddle on DIAMYD.ST into the EGM (or buy shares + protective puts). Anticipate IV to jump 40–80% around the vote; exit within 3 trading days post-meeting to harvest realized vol while avoiding directional exposure to implementation risk.